Carolina Schwab

Carolina Schwab

Auto-generated profile, based on publicly available information

Carolina Schwab

Department of Cardiology, Helios Frankenwaldklinik Kronach , Kronach , Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2022 in EP Europace
Verified
Journal Article
Open access
PDF file
ASAna Carolina Schwab
Ana Carolina Schwab
AAAnte Anic
Ante Anic
MFMichal Miroslaw Farkowski
Michal Miroslaw Farkowski
JGJose M Guerra
Jose M Guerra
KIKonstantinos E Iliodromitis
Konstantinos E Iliodromitis
SBSerge Boveda
Serge Boveda
Atrial fibrillation (AF) is a major challenge for the healthcare field. Pulmonary vein isolation is the most effective treatment for the maintenance of sinus rhythm. However, clinical endpoints for the procedure vary significantly among studies. There is no consensus on the definition of recurrence and no clear roadmap on how to deal with recurrences after a failed ablation. The purpose of this study was to perform a survey in order to show how clinicians currently approach this knowledge gap. An online survey, supported by the European Heart Rhythm Association (EHRA) Scientific Initiatives Committee, was conducted between 1 April 2022 and 8 May 2022. An anonymous questionnaire was disseminated via social media and EHRA newsletters, for clinicians to complete. This consisted of 18 multiple-choice questions regarding rhythm monitoring, definitions of a successful ablation, clinical practices after a failed AF ablation, and the continuance of anticoagulation. A total of 107 replies were collected across Europe. Most respondents (82%) perform routine monitoring for AF recurrences after ablation, with 51% of them preferring a long-term monitoring strategy. Cost was reported to have an impact on the choice of monitoring strategy. Self-screening was recommended by most (71%) of the respondents. The combination of absence of symptoms and recorded AF was the definition of success for most (83%) of the respondents. Cessation of anticoagulation after ablation was an option mostly for patients with paroxysmal AF and a low CHA2DS2-VASc score. The majority of physicians perform routine monitoring after AF ablation. For most physicians, the combination of the absence of symptoms and electrocardiographic endpoints defines a successful result after AF ablation.

21 December 2020
Verified
Preprint
Open access
CSCarolina Schwab
Carolina Schwab
MFMathias Forkmann
Mathias Forkmann
SBSteffi Butz
Steffi Butz
AVAneida Vevecka
Aneida Vevecka
DEDaniela Edler
Daniela Edler
SBSonia Busch
Sonia Busch
Background: Although atrial fibrillation (AF) ablation is a well-established treatment, the classical definition of recurrence and therefore success is not evidence-based. Additionally, the frequency of asymptomatic patients whose episodes are not noticed on routine electrocardiogram (ECG) may compromise the actual success rate. Objectives: This study aimed to assess the characteristics of AF burden after atrial fibrillation ablation and its influence on patients’ symptoms in the setting of continuous remote monitoring. It also sought to investigate a relevant cutoff as a new definition for recurrence. Methods: 141 consecutive patients with symptomatic paroxysmal or persistent AF underwent an AF ablation and then were followed by continuous rhythm monitoring. The AF/atrial tachycardia (AT) burden, duration of episodes and symptoms where registered systematically. Results: After the blanking period, freedom from AF/AT >30sec. was 59%. Considering an AF-Burden <1%, the success rate was 80%. The incidence of asymptomatic episodes in the group of patients with conventional recurrence was 24% (14/58) and 20% (8/41) when a cut-off of 1% of AF/AT burden was considered. Asymptomatic patients had an AF burden of 1.87 ± 4.6% during follow-up, compared to 4.0 ± 7.2% in symptomatic patients (p=0.02). There was no statistical difference between AF type (paroxysmal vs. persistent) and the frequency of asymptomatic episodes. Conclusions: Patients with asymptomatic AF Episodes represent a significant proportion after AF ablation. These patients could be easily overlooked without a proper monitoring technique. A burden cutoff of 1% and freedom from symptom should be considered as an ablation endpoint.

20 June 2017 in EP Europace
Verified
Journal Article
Open access
CSC. Schwab
C. Schwab
MFM. Forkmann
M. Forkmann
OTO. Turchner
O. Turchner
ASAhmed Saleh
Ahmed Saleh
SBS. Butz
S. Butz
SBS. Busch
S. Busch
Introduction: Pocket hematoma is one of the most common complications after pacemaker implantations, particularly in patients on either antiplatelet or oral anticoagulation therapies. It is also the most recognized risk factor for device infections. In the literature, pocket-hematoma incidence varies broadly, i. e., from 0.8 to 20%. The reason for such wide range seems to be the absence of measurable quantitative criteria and therefore no routine definition to hematoma.